Compare Nuwellis Inc (NUWE) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs RLX Technology Inc — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while RLX Technology Inc trades at $1.72 (market cap $2.10B). The key difference: RLX Technology Inc is far larger — about 954.5× Nuwellis Inc's market cap, and RLX Technology Inc pays a 5.81% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and RLX Technology Inc for 34 Days on average.
| NUWE | RLX | |
|---|---|---|
Market Cap | $2.20M | $2.10B |
Volume | 121,544 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $146.65 | $2.57 |
52-Week Low | $0.68 | $1.68 |
Typical Hold Time | 26 Days | 34 Days |
Enterprise Value | -$1.52M | $832.26M |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
RLX Technology trades at $1.73, near its 52-week low of $1.67, with bearish technical signals from moving averages. The company reported strong 2025 fundamentals with $921.87M net income and 21.87% net margin, though recent quarters show earnings misses. International expansion drives growth, with 70% of revenue now from overseas markets following European acquisitions.
The stock presents a value opportunity with discounted valuation multiples (P/E 15.46, P/B 0.91) but faces headwinds from recent earnings underperformance and bearish technical momentum. Key risks include margin compression and regulatory uncertainty in the e-vapor industry, while analyst sentiment remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
